Haydale Graphene Industries plc

("Haydale", "the Company" or the "Group")

Grant of share options and PDMR dealings

Haydale (AIM: HAYD), the global advanced materials group, announces that on 14 November 2022 the Company approved the following:

1.    under the 2020 EMI Scheme ("2020 EMI Scheme"), the grant of options to certain directors of the Company ("Directors"), certain directors of the Company's subsidiaries ("Subsidiary Directors") and staff of the Group, over an aggregate 45,950,000 ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"); and

2.    under the Haydale Technologies, Inc ("HTI") Stock Appreciation Rights Plan 2020 ("2020 SAR"), the grant of stock appreciation rights ("Stock Appreciation Rights") to certain employees of the Group's wholly owned US subsidiary, HTI, over an aggregate 8,750,000 Ordinary Shares.

(The 2020 EMI Scheme and the 2020 SAR , together the "Share Schemes". The new Options or Stock Appreciation Rights granted under the Share Schemes, together the "November 2022 Grants").

Background to the November 2022 Grants

The Company adopted the Share Schemes to enable it to retain and incentivise staff and to reward them for the achievement of its longer-term objectives. The Share Schemes have certain performance criteria to ensure that value is created for shareholders before any value is delivered to Directors and key staff.   The November 2022 Grants will extend the options of current option holders and also include those who have more recently joined the Group. 

Terms of the November 2022 Grants

All of the November 2022 Grants have an exercise price of 2.25p per Ordinary Share (being a 19.7% premium to the closing mid-market price of the Company's Ordinary Shares on 14 November 2022, the day of the approval of the November 2022 Grants) and can only be exercised between the third and tenth anniversary of the awards. The proportion of the awards made by the November 2022 Grants that are capable of vesting is dependent on certain performance criteria, directly linked to the performance of the Company's share price over the period to 30 September 2026 as follows:

There are no other vesting criteria for the November 2022 Grants. If the share price does not reach the target price by their respective dates, that portion of the award will lapse.

The November 2022 Grants represents approximately 6.9% of the Company's issued ordinary share capital. Of the November 2022 Grants, 28,900,000 options were granted to Directors of the Company and its subsidiaries, as follows:

The Company's Remuneration Committee retains the ability to amend the performance conditions for the November 2022 Grants and for future grants to ensure that such grants achieve the stated purpose.

Following the November 2022 Grants, the Company's total number of Options and SARs outstanding as at the date of this announcement is 102,000,000 representing approximately 12.97% of the Company's existing issued share capital and 9.78% on a fully diluted basis including all outstanding warrants.

The number of Ordinary Shares currently in issue is 785,852,475 and it is this number that has been used to calculate the above percentage shareholdings.

For further information:

Notes to Editors

Haydale is a global technologies and materials group that facilitates the integration of graphene and other nanomaterials into the next generation of commercial technologies and industrial materials.  With expertise in graphene, silicon carbide and other nanomaterials, Haydale is able to deliver improvements in electrical, thermal and mechanical properties, as well as toughness.  Haydale has granted patents for its technologies in Europe, USA, Australia, Japan and China and operates from six sites in the UK, USA and the Far East.

For more information please visit: www.haydale.com

Twitter: @haydalegraphene

The notification set out below is provided in accordance with the requirements of MAR.